Basic Cyclogest Information

• INN (International Nonproprietary Name): Progesterone.
• Brand Names Available In United Kingdom: Utrogestan (micronised progesterone capsules 100 mg, 200 mg).
• ATC Code: G03DA04.
• Forms & Dosages: Soft capsules 100 mg and 200 mg; vaginal capsules/softgels 100 mg and 200 mg; compounding powders (rare/custom).
• Manufacturers In United Kingdom: Major global suppliers include Besins Healthcare (Utrogestan), AbbVie (Prometrium) and several generic manufacturers (Teva, Mylan, Medochemie) as listed in international supplier data.
• Registration Status In United Kingdom: Registered in the EU/UK under multiple brand names; prescription status: prescription only (Rx).
• OTC / Rx Classification: Prescription only (Rx).

Latest Research Highlights (UK And EU)

Clinicians ask whether vaginal micronised progesterone matches intramuscular formulations for luteal support.

Recent UK and EU work between 2022 and 2025 has focused on three areas: luteal support in assisted reproduction, endometrial protection during combined HRT, and prevention of preterm birth in women with a short cervix.

Randomised trials from European IVF centres reported non‑inferiority of vaginal micronised progesterone compared with intramuscular progesterone for pregnancy and live birth outcomes.

Meta‑analyses published 2023–24 highlighted fewer systemic adverse events for micronised progesterone compared with some synthetic progestins used in HRT.

Safety surveillance across EU databases and MHRA Yellow Card trends emphasise sedation, mood changes and rare allergic reactions.

Available formulations include soft capsules and vaginal softgels in 100 mg and 200 mg strengths, ATC G03DA04.

These outcomes support use of micronised progesterone for luteal support and endometrial protection in appropriate patients.

Clinical Effectiveness In The UK

Fertility clinics and NHS teams commonly ask if vaginal progesterone affects success rates.

UK NHS practice uses micronised progesterone both orally and vaginally for HRT endometrial protection, secondary amenorrhoea and luteal support in IVF cycles.

Real‑world audits from UK fertility centres between 2022 and 2024 show comparable clinical pregnancy and live birth rates for vaginal progesterone against intramuscular progestogens.

Patient adherence tends to be higher with vaginal pessaries such as Cyclogest compared with painful IM injections.

For HRT, guidance aligned with MHRA and EMA recommends standard dosing such as 200 mg orally for 12 days per 28‑day cycle to prevent endometrial hyperplasia when given with oestrogen.

Patient‑reported outcomes in NHS portals and fertility forums show fewer mood and metabolic complaints with micronised progesterone versus certain synthetic progestins, although responses vary individually.

• Indication: Luteal support (IVF) — Regimen: Vaginal progesterone pessary 400 mg nightly or per clinic protocol — Efficacy: Comparable pregnancy rates to IM progesterone — Adverse: local discharge, mild irritation.
• Indication: HRT endometrial protection — Regimen: Oral 200 mg nightly for 12 days each 28‑day cycle — Efficacy: Prevents endometrial hyperplasia — Adverse: sedation, breast tenderness.
• Indication: Secondary amenorrhoea induction — Regimen: Oral 400 mg nightly for 10 days — Efficacy: Reliable withdrawal bleeding — Adverse: nausea, mood changes.

Indications And Expanded Uses

Clinicians want clear labelling versus common off‑label practice.

MHRA and EMA alignments list progesterone products for endometrial protection during combined oestrogen therapy and for treatment of secondary amenorrhoea, with specific brand labelling varying by product.

FDA approvals include secondary amenorrhoea and endometrial protection in postmenopausal women on oestrogen therapy.

Common NHS off‑label uses include vaginal administration of oral capsules for luteal support in IVF and in some recurrent miscarriage protocols.

Short‑course progesterone to induce withdrawal bleeding in amenorrhoea is widely used and supported by standard dosing regimens.

MHRA‑Labelled Uses

Endometrial protection with oestrogen; secondary amenorrhoea.

Common NHS Off‑Label Uses

Vaginal use of oral capsules for luteal support; recurrent miscarriage protocols in selected cases.

Evidence Strength

High for luteal support after ovulation or embryo transfer; moderate for preterm birth prophylaxis in women with short cervix; moderate for HRT endometrial protection when used at recommended doses.

Clinicians should follow local formularies and document informed consent for off‑label use.

Composition And Brand Landscape

Pharmacists check excipients and suppliers when dispensing or ordering stock.

The active ingredient is progesterone (INN: Progesterone) in micronised formulations to improve absorption.

The ATC code is G03DA04, classifying it among progestogens.

In the UK micronised progesterone is available under the Utrogestan brand in soft capsules 100 mg and 200 mg, with vaginal forms sold in some markets.

Major suppliers named in international registration data include Besins Healthcare (Utrogestan), AbbVie (Prometrium) and generic manufacturers such as Teva, Mylan and Medochemie.

Note that US packaging often carries a peanut allergen warning and EU packs often use the term “micronised” on the box.

Contraindications And Special Precautions

Always screen patients before supply or counselling.

Absolute contraindications include severe hepatic dysfunction, known or suspected hormone‑dependent malignancy such as breast cancer, undiagnosed vaginal bleeding, current or prior thrombosis (DVT, PE, stroke, MI), and allergy to capsule excipients such as peanut oil.

Relative contraindications that require monitoring are moderate hepatic or renal impairment, migraine, severe asthma, depression or other psychiatric disorders, and cardiovascular disease.

Practical pharmacist checks should include a pregnancy test if pregnancy is suspected and a detailed thrombosis and cancer history.

Medication review must check for hepatic enzyme inducers and other interacting medicines.

• Absolute Exclusion Criteria: Severe liver disease; known hormone‑dependent cancer; undiagnosed bleeding; history of thrombosis; excipient allergy (peanut oil).
• Monitor Closely If Present: Moderate hepatic/renal impairment; migraine; severe asthma; psychiatric history; cardiovascular disease.

Advise patients that sedation and drowsiness can occur and to avoid driving or operating machinery until their individual response is known.

Dosage Guidelines (NHS‑Oriented)

Clear dosing instructions reduce errors and improve adherence.

For secondary amenorrhoea the standard regimen is 400 mg orally at bedtime for 10 days and repeat monthly as prescribed.

For endometrial protection during HRT the common regimen is 200 mg orally at bedtime for 12 days of each 28‑day cycle when combined with oestrogen therapy.

For luteal support in fertility care, vaginal progesterone pessaries such as Cyclogest are often used at 400 mg nightly or as per local clinic protocol.

Vaginal administration of oral capsules is practised off‑label in some clinics.

Missed dose advice: take as soon as remembered unless close to the next scheduled dose; do not double up.

Overdose management is supportive; reported effects include nausea, sedation and withdrawal bleeding.

Interactions Overview

Drug interactions can reduce progesterone levels or increase side effects; ask about all medicines and herbal remedies.

Progesterone is metabolised hepatically and enzyme inducers such as rifampicin, carbamazepine, phenytoin, phenobarbital and St John’s Wort may lower progesterone concentrations and reduce efficacy.

Concurrent use with other CNS depressants or alcohol may increase sedation.

Oral contraceptives or other HRT regimens require review by the prescriber to avoid overlapping therapies or inappropriate dosing.

Use electronic prescribing checks (EPS and PMR) to flag interactions and document enzyme inducer use in fertility patients.

Cultural Perceptions And Patient Habits

Patients often ask whether "natural" progesterone is safer than synthetic options.

Many in the UK describe micronised progesterone as a more “natural” choice compared with synthetic progestins and seek it for better tolerability.

Online communities such as Patient.info and Mumsnet commonly discuss preferences for vaginal administration to minimise systemic effects.

Trust in pharmacist counselling is high and patients frequently consult pharmacies or NHS 111 before seeing their GP.

Fertility patients expect shared decision‑making, continuity of supply via EPS and home delivery from accredited services.

• Common Belief: Vaginal use causes fewer systemic effects.
• Evidence‑Based Response: Vaginal routes often give targeted endometrial exposure and may reduce systemic adverse events; individual response varies.
• Counselling Tip: Acknowledge patient preference, explain RCT evidence, and direct to NHS patient leaflets for balanced information.

Availability And Pricing Patterns

Access and cost vary by supply route and regional prescription policy.

In the UK micronised progesterone products such as Utrogestan and Cyclogest pessaries are prescription‑only, and community pharmacies such as Boots, LloydsPharmacy and Superdrug commonly dispense them when prescribed.

NHS prescription charging differs by nation within the UK and affects out‑of‑pocket cost: England applies per‑item charges (check NHS.uk for current rates), while Scotland, Wales and Northern Ireland provide free prescriptions for patients who meet their national criteria.

Private prescriptions and online pharmacies offer home delivery; electronic prescriptions (EPS) streamline collection from nominated pharmacies.

Branded products often cost more on private prescription than generics supplied via NHS procurement contracts.

In our online pharmacy, cyclogest is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Comparable Medicines And Preferences

Pharmacists and prescribers commonly compare micronised progesterone with synthetic progestins.

Alternatives include medroxyprogesterone (Provera) and dydrogesterone (Duphaston), both synthetic progestins with different receptor profiles and side‑effect patterns.

Micronised progesterone (Utrogestan, Cyclogest) is bioidentical to endogenous progesterone and is often preferred for tolerability in some patients due to less impact on lipids and mood in certain studies.

For luteal support, vaginal micronised progesterone is favoured for targeted endometrial effect and comfort, while IM progesterone gives high systemic levels but causes injection pain.

• Pros (Micronised Progesterone): Bioidentical, often better tolerated, available vaginally for targeted effect.
• Cons: Prescription status, potential excipient allergies (peanut oil in some formulations).
• Alternatives: Medroxyprogesterone (tablets/injectables) and dydrogesterone (oral tablets).

Local NHS formularies and clinician preference commonly guide choice; document reasons when switching agents.

Frequently Asked Questions

Q: Will Cyclogest or HRT progesterone make me sleepy?

A: Drowsiness and fatigue can occur with progesterone; avoid driving or operating machinery until you know how it affects you and discuss persistent sedation with your GP or pharmacist.

Q: Can I use vaginal progesterone if I’m trying to conceive?

A: Yes; vaginal progesterone is commonly used for luteal support in assisted reproduction and early pregnancy under clinic guidance—follow clinic dosing and inform your GP.

Q: Is micronised progesterone “natural” and safer than synthetic progestins?

A: Micronised progesterone is bioidentical and often better tolerated; evidence shows different side‑effect profiles versus synthetic progestins but safety depends on individual risk factors and indication.

Q: What should I do if I miss a dose?

A: Take the missed dose as soon as you remember unless it is near the time of the next dose; do not double up, and seek urgent help for severe reactions.

For more patient guidance, consult NHS.uk leaflets and local fertility clinic resources.

Guidelines For Proper Use (Pharmacist Counselling Style)

Pharmacists should use a brief, structured counselling approach for safe supply.

Confirm the indication and route of administration—oral versus vaginal—before handing over the medicine.

Check for absolute contraindications such as severe liver disease, hormone‑dependent cancer, thrombosis history and excipient allergies.

Review concomitant medicines for enzyme inducers and central nervous system depressants.

Advise patients to take doses at bedtime where appropriate to reduce sedation impact and to report red‑flag symptoms such as leg swelling, chest pain, severe mood changes or jaundice immediately.

Storage advice: keep below 25°C, protect from moisture and light, and retain in original packaging.

For vaginal pessaries such as Cyclogest provide a short demonstration: wash hands, remove wrapper, lie on back or stand with one leg raised, insert with finger as instructed, and remain supine for a short time if advised by clinic.

Use EPS to nominate a pharmacy for continuity and offer home delivery for fertility patients on multi‑cycle treatment.

Counselling Script:

1. “This is micronised progesterone, taken at bedtime unless your clinic advised otherwise.”
2. “Do not use if you have severe liver disease, active thrombosis or a peanut allergy to the excipient.”
3. “Expect possible drowsiness, breast tenderness or mood changes—tell us or your GP if these are severe.”
4. “If you miss a dose take it when you remember unless it is near the next dose; do not double up.”

Document counselling and any off‑label consent in the patient record.

Delivery Across United Kingdom